The application of cell therapy in treating degenerative diseases and cancer represents a significant breakthrough in modern medicine. However, the use of induced Pluripotent Stem Cells (iPSCs)Induced pluripotent stem cells presents several considerations, particularly challenges related to differentiation and instability. This chapter summarizes the preparation process from iPSC generation to preclinical animal trials before clinical application and provides a concise overview of current clinical cases involving iPSC-derived cells. First, we introduce the differences and differentiation potential between naïve and primed iPS cells, highlighting the significance of the reprogrammingreprogramming approach. We then discuss the immunogenic challenges associated with selecting appropriate cell sources for therapeutic applications, as these factors can influence the efficacy of graft transplantation. Next, we outline the preparation of preclinical animal trials, with an emphasis on safety considerations, which are critical for the therapeutic use of iPSC-derived cells. Additionally, this chapter explores emerging prospects, such as the automated production of iPSCsInduced pluripotent stem cells and their derivatives, to streamline processes and ensure consistent differentiation efficiency. Despite ongoing challenges in iPSC-based cell therapy that require further optimization, it holds great promise as a potential solution for degenerative disorders in the future.